The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.

Eli Lilly is buying Centessa Pharmaceuticals in a deal worth at least $6.3 billion, picking up a promising narcolepsy ...

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with ...

Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals ...

Narcolepsy is a rare condition that will make someone fall asleep abruptly — even in the middle of the day during an activity. It's possible to treat narcolepsy and manage your symptoms with lifestyle ...

CEO Richard Pops said the company is entering what he described as a “really exciting year” as the orexin agonist field moves ...

Amanda Myers is a senior at the University of Florida majoring in pre-veterinary studies. She is also a competitive weightlifter, and a speaker for Project Sleep's Rising Voices of Narcolepsy program.

Narcolepsy is a rare disorder of central hypersomnolence which is often under-recognised owing to a variable clinical phenotype. Narcolepsy type 1 (NT1) is caused by loss of hypothalamic hypocretin ...

As a sleep specialist, I find it incredibly rewarding to treat people with narcolepsy. It can be unnerving to be diagnosed with the disorder. But it’s also a huge relief, because people finally know ...